REFERENCES

1. Beaglehole R. Cardiovascular disease in developing countries. *BMJ*. 1992;305:1170-1171.

2. World Health Organization. Ten statistical highlights in global public health. 9-20. 2007. Geneva.

3. Chambless L, Keil U, Dobson A, Mahonen M, Kuulasmaa K, Rajakangas AM, Lowel H, Tunstall-Pedoe H. Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990. Multinational MONItoring of Trends and Determinants in CArdiovascular Disease. *Circulation*. 1997;96:3849-3859.

4. Panteghini M. Role and importance of biochemical markers in clinical cardiology. *Eur Heart J*. 2004;25:1187-1196.

5. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. *Circulation*. 2002;105:1760-1763.

6. Ng LL, Loke IW, O'Brien RJ, Squire IB, Davies JE. Plasma urocortin in human systolic heart failure. *Clin Sci (Lond)*. 2004;106:383-388.

7. Parkes DG, Vaughan J, Rivier J, Vale W, May CN. Cardiac inotropic actions of urocortin in conscious sheep. *Am J Physiol*. 1997;272:H2115-H2122.

8. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, Vale WW, Peterson KL. The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. *Proc Natl Acad Sci U S A*. 2004;101:3697-3702.

9. Davis ME, Pemberton CJ, Yandle TG, Lainchbury JG, Rademaker MT, Nicholls MG, Frampton CM, Richards AM. Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. *Clin Sci (Lond)*. 2005;109:381-388.

10. Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatrick CM, Lainchbury JG, Nicholls MG, Richards AM, Vale WW. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. *J Am Coll Cardiol*. 2002;40:1495-1505.

11. Brar BK, Stephanou A, Okosi A, Lawrence KM, Knight RA, Marber MS, Latchman DS. CRH-like peptides protect cardiac myocytes from lethal ischaemic injury. *Mol Cell Endocrinol*. 1999;158:55-63.

12. Brar BK, Jonassen AK, Stephanou A, Santilli G, Railson J, Knight RA, Yellon DM, Latchman DS. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. *J Biol Chem*. 2000;275:8508-8514.

13. Cave AC, Hearse DJ. Ischaemic preconditioning and contractile function: studies with normothermic and hypothermic global ischaemia. *J Mol Cell Cardiol*. 1992;24:1113-1123.

14. Vegh A, Szekeres L, Parratt JR. Protective effects of preconditioning of the ischaemic myocardium involve cyclo-oxygenase products. *Cardiovasc Res*. 1990;24:1020-1023.

15. Sharma A, Singh M. Effect of ethylisopropyl amiloride, a Na+ - H+ exchange inhibitor, on cardioprotective effect of ischaemic and angiotensin preconditioning. *Mol Cell Biochem*. 2000;214:31-38.

16. Knight RA, Chen-Scarabelli C, Yuan Z, McCauley RB, Di Rezze J, Scarabelli GM, Townsend PA, Latchman D, Saravolatz L, Faggian G, Mazzucco A, Chowdrey HS, Stephanou A, Scarabelli TM. Cardiac release of urocortin precedes the occurrence of irreversible myocardial damage in the rat heart exposed to ischemia/reperfusion injury. *FEBS Lett*. 2008;582:984-990.

17. Florio P, Reis FM, Torres PB, Calonaci F, Toti P, Bocchi C, Linton EA, Petraglia F. Plasma urocortin levels in the diagnosis of ovarian endometriosis. *Obstet Gynecol*. 2007;110:594-600.

18. Scarabelli TM, Pasini E, Stephanou A, Comini L, Curello S, Raddino R, Ferrari R, Knight R, Latchman DS. Urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ischemia/reperfusion. *J Am Coll Cardiol*. 2002;40:155-161.

19. Ikeda K, Tojo K, Tokudome G, Ohta M, Sugimoto K, Tamura T, Tajima N, Mochizuki S, Kawakami M, Hosoya T. Cardiac expression of urocortin (Ucn) in diseased heart; preliminary results on possible involvement of Ucn in pathophysiology of cardiac diseases. *Mol Cell Biochem*. 2003;252:25-32.

20. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S, Yutani C, Matsuo H, Matsuoka H, Kangawa K. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. *Am J Physiol Heart Circ Physiol*. 2000;279:H3031-H3039.

21. Watanabe F, Oki Y, Ozawa M, Masuzawa M, Iwabuchi M, Yoshimi T, Nishiguchi T, Iino K, Sasano H. Urocortin in human placenta and maternal plasma. *Peptides*. 1999;20:205-209.

22. Grech ED, Ramsdale DR. Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. *BMJ*. 2003;326:1259-1261.

23. Alexander JH, Sparapani RA, Mahaffey KW, Deckers JW, Newby LK, Ohman EM, Corbalan R, Chierchia SL, Boland JB, Simoons ML, Califf RM, Topol EJ, Harrington RA. Association between minor elevations of creatine kinase-

MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. *JAMA*. 2000;283:347-353.

24. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van Der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernandez-Aviles F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Sechtem U, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al Attar N. Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. *Eur Heart J*. 2007;28:2525-2538.

25. Libby P, Theroux P. Pathophysiology of coronary artery disease. *Circulation*. 2005;111:3481-3488.

26. Alan HB Wu. Early detection of acute coronary syndromes and risk stratification by multimarker analysis. 1(1), 45-57. 2007. Biomarkers Med.

27. Norris RM. Fatality outside hospital from acute coronary events in three British health districts, 1994-5. United Kingdom Heart Attack Study Collaborative Group. *BMJ*. 1998;316:1065-1070.

28. Wong CK, White HD. Has the mortality rate from acute myocardial infarction fallen substantially in recent years? *Eur Heart J*. 2002;23:689-692.

29. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de WF, Avezum A, Goodman SG, Flather MD, Anderson FA, Jr., Granger CB. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). *BMJ*. 2006;333:1091.

30. Gillum RF, Fortmann SP, Prineas RJ, Kottke TE. International diagnostic criteria for acute myocardial infarction and acute stroke. *Am Heart J*. 1984;108:150-158.

31. Wang K, Asinger RW, Marriott HJ. ST-segment elevation in conditions other than acute myocardial infarction. *N Engl J Med*. 2003;349:2128-2135.

32. Hojo Y, Ikeda U, Ueno S, Arakawa H, Shimada K. Expression of matrix metalloproteinases in patients with acute myocardial infarction. *Jpn Circ J*. 2001;65:71-75.

33. Kleinfeld AM, Prothro D, Brown DL, Davis RC, Richieri GV, DeMaria A. Increases in serum unbound free fatty acid levels following coronary angioplasty. *Am J Cardiol*. 1996;78:1350-1354.

34. Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, Pagani F, Christenson RH, Mockel M, Danne O, Jaffe AS. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. *Clin Chem*. 2005;51:810-824.

35. Collinson PO, Gaze DC. Biomarkers of cardiovascular damage and dysfunction--an overview. *Heart Lung Circ*. 2007;16 Suppl 3:S71-S82.

36. Bar-Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. *Eur J Biochem*. 2001;268:42-47.

37. Christenson RH, Duh SH, Sanhai WR, Wu AH, Holtman V, Painter P, Branham E, Apple FS, Murakami M, Morris DL. Characteristics of an Albumin Cobalt Binding Test for assessment of acute coronary syndrome patients: a multicenter study. *Clin Chem*. 2001;47:464-470.

38. Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. *Circulation*. 2003;107:2403-2405.

39. Collinson PO, Gaze DC. Biomarkers of cardiovascular damage. *Med Princ Pract*. 2007;16:247-261.

40. Innes G. Clinical utility of novel cardiac markers: let the buyer beware. *CJEM*. 2006;8:32-36.

41. Zapico-Muniz E, Santalo-Bel M, Merce-Muntanola J, Montiel JA, Martinez-Rubio A, Ordonez-Llanos J. Ischemia-modified albumin during skeletal muscle ischemia. *Clin Chem*. 2004;50:1063-1065.

42. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. *J Am Coll Cardiol*. 2003;41:37S-42S.

43. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, Castro L, Lusis AJ, Nauseef WM, White CR, Freeman BA. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. *Science*. 2002;296:2391-2394.

44. Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, Winterbourn CC. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. *J Am Coll Cardiol*. 2007;49:1993-2000.

45. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, Simoons ML, Hamm CW. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. *Circulation*. 2003;108:1440-1445.

46. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL. Prognostic value of myeloperoxidase in patients with chest pain. *N Engl J Med*. 2003;349:1595-1604.

47. Biasucci LM, D'Onofrio G, Liuzzo G, Zini G, Monaco C, Caligiuri G, Tommasi M, Rebuzzi AG, Maseri A. Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. *J Am Coll Cardiol*. 1996;27:611-616.

48. Donald Schreiber and Suzanne M Miller. Use of Cardiac Markers in the Emergency Department. Edward Bessman, Francisco Talavera, Gary Setnik, John Halamka, and Jonathan Adler. http://www.emedicine.com/emerg/topic932.htm . 26-6-2006. 23-11-2007.

49. van der Veen KJ, Willebrands AF. Isoenzymes of creatine phosphokinase in tissue extracts and in normal and pathological sera. *Clin Chim Acta*. 1966;13:312-316.

50. Mercer DW. Role of cardiac markers in evaluation of suspected myocardial infarction. Selecting the most clinically useful indicators. *Postgrad Med*. 1997;102:113-2.

51. Karras DJ, Kane DL. Serum markers in the emergency department diagnosis of acute myocardial infarction. *Emerg Med Clin North Am*. 2001;19:321-337.

52. Brogan GX, Jr., Hollander JE, McCuskey CF, Thode HC, Jr., Snow J, Sama A, Bock JL. Evaluation of a new assay for cardiac troponin I vs creatine kinase-MB for the diagnosis of acute myocardial infarction. Biochemical Markers for Acute Myocardial Ischemia (BAMI) Study Group. *Acad Emerg Med*. 1997;4:6-12.

53. Hollander JE, Levitt MA, Young GP, Briglia E, Wetli CV, Gawad Y. Effect of recent cocaine use on the specificity of cardiac markers for diagnosis of acute myocardial infarction. *Am Heart J*. 1998;135:245-252.

54. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Potential value for new diagnostic markers in the early recognition of acute coronary syndromes. *CJEM*. 2006;8:27-31.

55. French JK, White HD. Clinical implications of the new definition of myocardial infarction. *Heart*. 2004;90:99-106.

56. Wu, A. H. Early detection of acute coronary syndromes and risk stratification by multimarker analysis. http://www.futuremedicine.com/doi/abs/10.2217/17520363.1.1.45 1(1), 45-57. 2007. *Biomarkers in Medicine*. 3-10-2008.

57. Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS, Galvani M, Katus H. It's time for a change to a troponin standard. *Circulation*. 2000;102:1216-1220.

58. Wong CK, White HD. Myocardial infarction: why can't we get the diagnosis right? *Eur Heart J*. 2003;24:1177-1179.

59. Achar SA, Kundu S, Norcross WA. Diagnosis of acute coronary syndrome. *Am Fam Physician*. 2005;72:119-126.

60. Wu AH. Cardiac markers: from enzymes to proteins, diagnosis to prognosis, laboratory to bedside. *Ann Clin Lab Sci*. 1999;29:18-23.

61. Panteghini M, Pagani F, Bonetti G. The sensitivity of cardiac markers: an evidence-based approach. *Clin Chem Lab Med*. 1999;37:1097-1106.

62. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. *J Am Coll Cardiol*. 2006;48:1-11.

63. Wu AH, Feng YJ, Contois JH, Pervaiz S. Comparison of myoglobin, creatine kinase-MB, and cardiac troponin I for diagnosis of acute myocardial infarction. *Ann Clin Lab Sci*. 1996;26:291-300.

64. Wu AH, Clive JM. Impact of CK-MB testing policies on hospital length of stay and laboratory costs for patients with myocardial infarction or chest pain. *Clin Chem*. 1997;43:326-332.

65. Januzzi JL, Jr., Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. *Am J Cardiol*. 2005;95:948-954.

66. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. *Circulation*. 2002;105:2392-2397.

67. Krauser DG, Lloyd-Jones DM, Chae CU, Cameron R, Anwaruddin S, Baggish AL, Chen A, Tung R, Januzzi JL, Jr. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. *Am Heart J*. 2005;149:744-750.

68. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, Herrmann HC, Steg PG, Westheim A, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. *Am J Kidney Dis*. 2003;41:571-579.

69. Brown AM, Sease KL, Robey JL, Shofer FS, Hollander JE. The impact of B-type natriuretic peptide in addition to troponin I, creatine kinase-MB, and myoglobin on the risk stratification of emergency department chest pain patients with potential acute coronary syndrome. *Ann Emerg Med*. 2007;49:153-163.

70. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. *N Engl J Med*. 2001;345:1014-1021.

71. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. *Circulation*. 1998;97:1921-1929.

72. Sanja Dacic and Mohamed A Virji. Profiles of Total CK, CK-MB and Troponin I in Acute Myocardial Infarction (AMI). http://path.upmc.edu/cases/case178/images/micro.JPG . 22-11-2007. Department of Pathology, University of Pittsburgh School of Medicine. 22-11-2007.

73. Worster A, Devereaux PJ, Heels-Ansdell D, Guyatt GH, Opie J, Mookadam F, Hill SA. Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome. *CMAJ*. 2005;172:1685-1690.

74. Zaninotto M, Mion MM, Novello E, Altinier S, Plebani M. New biochemical markers: from bench to bedside. *Clin Chim Acta*. 2007;381:14-20.

75. Apple FS, Quist HE, Murakami MM. Diagnostic and prognostic value of cardiac troponin I assays in patients admitted with symptoms suggestive of acute coronary syndrome. *Arch Pathol Lab Med*. 2004;128:430-434.

76. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. *Science*. 1981;213:1394-1397.

77. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C, . Urocortin, a mammalian neuropeptide

related to fish urotensin I and to corticotropin-releasing factor. *Nature*. 1995;378:287-292.

78. Donaldson CJ, Sutton SW, Perrin MH, Corrigan AZ, Lewis KA, Rivier JE, Vaughan JM, Vale WW. Cloning and characterization of human urocortin. *Endocrinology*. 1996;137:2167-2170.

79. Latchman DS. Urocortin. *Int J Biochem Cell Biol*. 2002;34:907-910.

80. Parkes DG, May CN. Urocortin: A Novel Player in Cardiac Control. *News Physiol Sci*. 2000;15:264-268.

81. Scarabelli T, Knight R. Urocortins: take them to heart. *Curr Med Chem Cardiovasc Hematol Agents*. 2004;2:335-342.

82. Kimura Y, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, Darnel AD, Suzuki T, Ebina M, Nukiwa T, Sasano H. Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. *J Clin Endocrinol Metab*. 2002;87:340-346.

83. Fekete EM, Zorrilla EP. Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. *Front Neuroendocrinol*. 2007;28:1-27.

84. Takahashi K. Translational medicine in fish-derived peptides: from fish endocrinology to human physiology and diseases. *Endocr J*. 2004;51:1-17.

85. Huang Y, Yao XQ, Lau CW, Chan YC, Tsang SY, Chan FL. Urocortin and cardiovascular protection. *Acta Pharmacol Sin*. 2004;25:257-265.

86. Ikeda K, Tojo K, Sato S, Ebisawa T, Tokudome G, Hosoya T, Harada M, Nakagawa O, Nakao K. Urocortin, a newly identified corticotropin-releasing factor-related mammalian peptide, stimulates atrial natriuretic peptide and brain natriuretic peptide secretions from neonatal rat cardiomyocytes. *Biochem Biophys Res Commun*. 1998;250:298-304.

87. Gonzalez-Rey E, Chorny A, Varela N, Robledo G, Delgado M. Urocortin and adrenomedullin prevent lethal endotoxemia by down-regulating the inflammatory response. *Am J Pathol*. 2006;168:1921-1930.

88. Kim YD, Fomsgaard JS, Heim KF, Ramwell PW, Thomas G, Kagan E, Moore SP, Coughlin SS, Kuwahara M, Analouei A, . Brief ischemia-reperfusion induces stunning of endothelium in canine coronary artery. *Circulation*. 1992;85:1473-1482.

89. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC, Anversa P. Apoptosis in the failing human heart. *N Engl J Med*. 1997;336:1131-1141.

90. Valentim L, Laurence KM, Townsend PA, Carroll CJ, Soond S, Scarabelli TM, Knight RA, Latchman DS, Stephanou A. Urocortin inhibits Beclin1-mediated autophagic cell death in cardiac myocytes exposed to ischaemia/reperfusion injury. *J Mol Cell Cardiol*. 2006;40:846-852.

91. Garcia-Villalon AL, Sanz E, Monge L, Fernandez N, Climent B, Dieguez G. Urocortin protects coronary endothelial function during ischemia-reperfusion: a brief communication. *Exp Biol Med (Maywood)*. 2004;229:118-120.

92. Garcia-Villalon AL, Amezquita YM, Monge L, Fernandez N, Climent B, Sanchez A, Dieguez G. Mechanisms of the protective effects of urocortin on coronary endothelial function during ischemia-reperfusion in rat isolated hearts. *Br J Pharmacol*. 2005;145:490-494.

93. Grossini E, Molinari C, Mary DA, Marino P, Vacca G. The effect of urocortin II administration on the coronary circulation and cardiac function in the anaesthetized pig is nitric-oxide-dependent. *Eur J Pharmacol*. 2008;578:242-248.

94. Berning J, Steensgaard-Hansen F. Early estimation of risk by echocardiographic determination of wall motion index in an unselected population with acute myocardial infarction. *Am J Cardiol*. 1990;65:567-576.

95. Lionel H.Opie, Mark G.Perlroth. Ventricular Function. In: Heart Physiology From Cell to Circulation. Lionel H.Opie, ed. 2004. Lippincott Williams & Wilkins.

96. Richard E.Klabunde. Cardiovascular physiology concepts. http://www.cvphysiology.com/index.html . 4-3-2007. 20-12-2007.

97. Arnold M.Katz. Physiology of the heart. 2006. Lippincott Williams & Wilkins, Philadelphia.

98. Killip T, III, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. *Am J Cardiol*. 1967;20:457-464.

99. Ramachandran S.Vasan. Biomarkers of cardiovascular disease molecular basis and practical considerations. *Circulation*. 2006;2335-2362.

100. Pan W, Kastin AJ. Urocortin and the brain. *Prog Neurobiol*. 2008;84:148-156.

101. Lefer AM, Tsao PS, Lefer DJ, Ma XL. Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia. *FASEB J*. 1991;5:2029-2034.

102. Miki I, Seya K, Motomura S, Furukawa K. Role of corticotropin-releasing factor receptor type 2 beta in urocortin-induced vasodilation of rat aortas. *J Pharmacol Sci*. 2004;96:170-176.

103. Terui K, Higashiyama A, Horiba N, Furukawa KI, Motomura S, Suda T. Coronary vasodilation and positive inotropism by urocortin in the isolated rat heart. *J Endocrinol*. 2001;169:177-183.

104. Schulman D, Latchman DS, Yellon DM. Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. *Am J Physiol Heart Circ Physiol*. 2002;283:H1481-H1488.

105. Ogawa A, Seino Y, Yamashita T, Ogata K, Takano T. Difference in elevation of N-terminal pro-BNP and conventional cardiac markers between patients with ST elevation vs non-ST elevation acute coronary syndrome. *Circ J*. 2006;70:1372-1378.

106. Terkelsen CJ, Lassen JF, Norgaard BL, Gerdes JC, Jensen T, Gotzsche LB, Nielsen TT, Andersen HR. Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort. *Eur Heart J*. 2005;26:18-26.

107. Tran H, Mehta SR, Eikelboom JW. Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI). *Vasc Health Risk Manag*. 2006;2:379-387.

108. Bode C, Zirlik A. STEMI and NSTEMI: the dangerous brothers. *Eur Heart J*. 2007;28:1403-1404.

109. Antonicelli R, Olivieri F, Cavallone L, Spazzafumo L, Bonafe M, Marchegiani F, Cardelli M, Galeazzi R, Giovagnetti S, Perna GP, Franceschi C. Tumor necrosis factor-alpha gene -308G>A polymorphism is associated with ST-elevation myocardial infarction and with high plasma levels of biochemical ischemia markers. *Coron Artery Dis*. 2005;16:489-493.

110. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM, Rademaker MT, Richards AM. Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses. *J Am Coll Cardiol*. 2007;49:461-471.

111. Rademaker MT, Cameron VA, Charles CJ, Richards AM. Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. *Circulation*. 2005;112:3624-3632.

112. Arakawa N, Nakamura M, Aoki H, Hiramori K. Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. *Cardiology*. 1994;85:334-340.

113. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. *N Engl J Med*. 1997;336:1276-1282.

114. Biasucci LM, Leo M, De Maria GL. Local and Systemic Mechanisms of Plaque Rupture. *Angiology*. 2008.

115. Lutgens E, van Suylen RJ, Faber BC, Gijbels MJ, Eurlings PM, Bijnens AP, Cleutjens KB, Heeneman S, Daemen MJ. Atherosclerotic plaque rupture: local or systemic process? *Arterioscler Thromb Vasc Biol*. 2003;23:2123-2130.

116. Kiss K, Khanakah G, Kundi M, Glogar HD, Stanek G. Increase of chlamydial LPS antibodies in patients with acute coronary syndrome without detection of chlamydial DNA in atherectomy samples. *Wien Klin Wochenschr*. 2001;113:731-736.

117. Elmas E, Holzer L, Lang S, Popp T, Kalsch T, Wolpert C, Brueckmann M, Borggrefe M. Enhanced proinflammatory response of mononuclear cells to in vitro LPS-challenge in patients with ventricular fibrillation in the setting of acute myocardial infarction. *Cytokine*. 2008.

118. Sugishita Y, Shimizu T, Yao A, Kinugawa K, Nojiri T, Harada K, Matsui H, Nagai R, Takahashi T. Lipopolysaccharide augments expression and secretion of vascular endothelial growth factor in rat ventricular myocytes. *Biochem Biophys Res Commun*. 2000;268:657-662.

119. Kageyama K, Gaudriault GE, Bradbury MJ, Vale WW. Regulation of corticotropin-releasing factor receptor type 2 beta messenger ribonucleic acid

in the rat cardiovascular system by urocortin, glucocorticoids, and cytokines. *Endocrinology*. 2000;141:2285-2293.